Literature DB >> 21168021

Does early surgical intervention improve left ventricular mass regression after mitral valve repair for leaflet prolapse?

John M Stulak1, Rakesh M Suri, Joseph A Dearani, Harold M Burkhart, Thoralf M Sundt, Maurice Enriquez-Sarano, Hartzell V Schaff.   

Abstract

BACKGROUND: Left ventricular hypertrophy is associated with adverse cardiovascular outcomes. It is unclear whether hypertrophy caused by severe chronic mitral regurgitation regresses after mitral valve repair and, if so, which factors promote reverse remodeling and influence its prognostic significance.
METHODS: Between March 1995 and December 2005, 2589 patients had mitral valve repair. Five hundred thirty patients (346 of whom were male) underwent isolated repair for leaflet prolapse and had echocardiographic data available from which the left ventricular mass index could be calculated. Concomitant preoperative tricuspid valve regurgitation was more than mild in 95 (18%) patients. Those with preoperative atrial fibrillation and other cardiac pathologies necessitating intracardiac repair were not included.
RESULTS: Significant regression of left ventricular mass index occurred during the first 3 years (-28 g/m(2), P < .001) and was maintained during follow-up for more than 3 years (-26 g/m(2), P < .001). Higher preoperative left ventricular ejection fraction and greater preoperative left ventricular mass index independently predicted improved left ventricular mass index regression at 3 years. During follow-up of greater than 3 years, greater preoperative left ventricular mass index persisted in predicting improved mass regression (P < 0.001), and greater than mild preoperative tricuspid valve regurgitation was associated with less mass regression (P < .001). Late recovery of normal left ventricular ejection fraction was impaired in those with the greatest residual left ventricular mass; however, there was no difference in late symptoms or survival.
CONCLUSIONS: Performing mitral valve repair before a decrease in left ventricular ejection fraction and the development of significant secondary tricuspid valve regurgitation is associated with a greater likelihood of significant regression of left ventricular mass, possibly predicting improved recovery of normal left ventricular function after surgical intervention. These data provide additional support for early degenerative mitral valve repair.
Copyright © 2011 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21168021     DOI: 10.1016/j.jtcvs.2010.08.068

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  4 in total

1.  Changes in left ventricular morphology and function after mitral valve surgery.

Authors:  Alexis E Shafii; A Marc Gillinov; Tomislav Mihaljevic; William Stewart; Lillian H Batizy; Eugene H Blackstone
Journal:  Am J Cardiol       Date:  2012-04-23       Impact factor: 2.778

2.  Quantitative evaluation of change in coexistent mitral regurgitation after aortic valve replacement.

Authors:  David J Kaczorowski; John W Macarthur; Jessica Howard; Dale Kobrin; Alex Fairman; Y Joseph Woo
Journal:  J Thorac Cardiovasc Surg       Date:  2012-12-11       Impact factor: 5.209

3.  Stage-based approach to predict left ventricular reverse remodeling after mitral repair.

Authors:  Makoto Hibino; Nitish K Dhingra; Vincent Chan; C David Mazer; Hwee Teoh; Adrian Quan; Raj Verma; Howard Leong-Poi; Gianluigi Bisleri; Kim A Connelly; Subodh Verma
Journal:  Clin Cardiol       Date:  2022-06-24       Impact factor: 3.287

4.  Late plasma exosome microRNA-21-5p depicts magnitude of reverse ventricular remodeling after early surgical repair of primary mitral valve regurgitation.

Authors:  Fausto Pizzino; Giulia Furini; Valentina Casieri; Massimiliano Mariani; Giacomo Bianchi; Simona Storti; Dante Chiappino; Stefano Maffei; Marco Solinas; Giovanni Donato Aquaro; Vincenzo Lionetti
Journal:  Front Cardiovasc Med       Date:  2022-07-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.